应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INZY Inozyme Pharma
停牌 07-11 11:00:16 EDT
4.00
+0.00
0.00%
最高
4.00
最低
4.00
成交量
0.00
今开
4.00
昨收
4.00
日振幅
0.00%
总市值
2.60亿
流通市值
1.21亿
总股本
6,492万
成交额
583.42万
换手率
0.00%
流通股本
3,015万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Inozyme Pharma, Inc.6月16日成交额为278.94万美元
市场透视 · 06-17
Inozyme Pharma, Inc.6月16日成交额为278.94万美元
Inozyme Pharma, Inc.6月13日成交额为172.37万美元
市场透视 · 06-14
Inozyme Pharma, Inc.6月13日成交额为172.37万美元
Inozyme Pharma, Inc.6月11日成交额为154.62万美元
市场透视 · 06-12
Inozyme Pharma, Inc.6月11日成交额为154.62万美元
Inozyme Pharma, Inc.6月10日成交额为366.18万美元
市场透视 · 06-11
Inozyme Pharma, Inc.6月10日成交额为366.18万美元
Inozyme Pharma, Inc.6月9日成交额为411.56万美元
市场透视 · 06-10
Inozyme Pharma, Inc.6月9日成交额为411.56万美元
Inozyme Pharma, Inc.6月6日成交额为179.90万美元
市场透视 · 06-07
Inozyme Pharma, Inc.6月6日成交额为179.90万美元
Inozyme Pharma, Inc.6月4日成交额为593.95万美元
市场透视 · 06-05
Inozyme Pharma, Inc.6月4日成交额为593.95万美元
Inozyme Pharma, Inc.6月3日成交额为407.81万美元
市场透视 · 06-04
Inozyme Pharma, Inc.6月3日成交额为407.81万美元
Inozyme Pharma, Inc.6月2日成交额为715.95万美元
市场透视 · 06-03
Inozyme Pharma, Inc.6月2日成交额为715.95万美元
Inozyme Pharma, Inc.5月29日成交额为1513.01万美元
市场透视 · 05-30
Inozyme Pharma, Inc.5月29日成交额为1513.01万美元
Inozyme Pharma, Inc.5月27日成交额为452.94万美元
市场透视 · 05-28
Inozyme Pharma, Inc.5月27日成交额为452.94万美元
Inozyme制药公司和Biohaven制药公司宣布在行业重组期间进行领导层变动相关的帖子:Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring Related posts:
动脉网 · 05-26
Inozyme制药公司和Biohaven制药公司宣布在行业重组期间进行领导层变动相关的帖子:Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring Related posts:
Inozyme Pharma, Inc.5月23日成交额为458.83万美元
市场透视 · 05-24
Inozyme Pharma, Inc.5月23日成交额为458.83万美元
Inozyme Pharma, Inc.2025财年第一财季实现净利润-28.04百万美元,同比减少20.09%
市场透视 · 05-22
Inozyme Pharma, Inc.2025财年第一财季实现净利润-28.04百万美元,同比减少20.09%
Inozyme Pharma, Inc.5月21日成交额为1010.99万美元
市场透视 · 05-22
Inozyme Pharma, Inc.5月21日成交额为1010.99万美元
Inozyme Pharma, Inc.5月20日成交额为2507.22万美元
市场透视 · 05-21
Inozyme Pharma, Inc.5月20日成交额为2507.22万美元
Inozyme Pharma, Inc.5月19日成交额为3246.92万美元
市场透视 · 05-20
Inozyme Pharma, Inc.5月19日成交额为3246.92万美元
Needham:下调Inozyme Pharma评级
证券之星 · 05-16
Needham:下调Inozyme Pharma评级
Inozyme Pharma, Inc.盘中异动 早盘快速拉升177.46%报3.94美元
市场透视 · 05-16
Inozyme Pharma, Inc.盘中异动 早盘快速拉升177.46%报3.94美元
Needham:维持Inozyme Pharma评级,由买入调整至买入评级, 目标价由15.00美元调整至12.00美元。
金融界 · 05-14
Needham:维持Inozyme Pharma评级,由买入调整至买入评级, 目标价由15.00美元调整至12.00美元。
加载更多
公司概况
公司名称:
Inozyme Pharma
所属市场:
NASDAQ
上市日期:
--
主营业务:
Inozyme Pharma, Inc.根据特拉华州法律成立于2015年9月。该公司是一家罕见的疾病生物制药公司,致力于开发新颖的疗法来治疗影响血管,软组织和骨骼的异常矿化疾病。通过对矿化所涉及的生物途径的深入了解,该公司致力于开发治疗剂以解决这些使人衰弱的疾病的根本原因。
发行价格:
--
{"stockData":{"symbol":"INZY","market":"US","secType":"STK","nameCN":"Inozyme Pharma","latestPrice":4,"timestamp":1751313600000,"preClose":4,"halted":3,"volume":0,"delay":0,"floatShares":30148186,"shares":64915697,"eps":-1.682199,"marketStatus":"停牌","change":0,"latestTime":"07-11 11:00:16 EDT","open":4,"high":4,"low":4,"amount":5834241.3154944,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.682199,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1752264000000},"marketStatusCode":2,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":4,"volumeRatio":0},"requestUrl":"/m/hq/s/INZY","defaultTab":"news","newsList":[{"id":"2544935005","title":"Inozyme Pharma, Inc.6月16日成交额为278.94万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544935005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544935005?lang=zh_cn&edition=full","pubTime":"2025-06-17 10:52","pubTimestamp":1750128723,"startTime":"0","endTime":"0","summary":"美东时间2025年6月16日,Inozyme Pharma, Inc.成交额为278.94万美元,成交额较昨日增加61.83%,当日成交量为70.11万股。Inozyme Pharma, Inc.于2025年6月16日跌0.5%,报3.97美元,该股过去5个交易日跌0.25%,年初至今涨43.32%,过去60日涨315.71%。该公司专注于开发一种新型疗法,以治疗 ENPP1 和 ABCC6 缺陷的罕见遗传病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617105210a4ad55f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617105210a4ad55f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2543547036","title":"Inozyme Pharma, Inc.6月13日成交额为172.37万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543547036","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543547036?lang=zh_cn&edition=full","pubTime":"2025-06-14 10:47","pubTimestamp":1749869256,"startTime":"0","endTime":"0","summary":"美东时间2025年6月13日,Inozyme Pharma, Inc.成交额为172.37万美元,成交额较昨日增加43.19%,当日成交量为43.27万股。Inozyme Pharma, Inc.于2025年6月13日涨0.25%,报3.99美元,该股过去5个交易日涨0.0%,年初至今涨44.04%,过去60日涨299.4%。该公司专注于开发一种新型疗法,以治疗 ENPP1 和 ABCC6 缺陷的罕见遗传病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614104743a4a88fa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614104743a4a88fa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2542730550","title":"Inozyme Pharma, Inc.6月11日成交额为154.62万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542730550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542730550?lang=zh_cn&edition=full","pubTime":"2025-06-12 10:38","pubTimestamp":1749695936,"startTime":"0","endTime":"0","summary":"美东时间2025年6月11日,Inozyme Pharma, Inc.成交额为154.62万美元,成交额较昨日减少57.78%,当日成交量为38.89万股。Inozyme Pharma, Inc.于2025年6月11日跌0.25%,报3.97美元,该股过去5个交易日跌0.25%,年初至今涨43.32%,过去60日涨289.22%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-11|154.62万|-57.78%|38.89万|#|2025-06-10|366.18万|-11.03%|92.05万|#|2025-06-09|411.56万|128.77%|103.42万|#|2025-06-06|179.90万|-61.75%|45.10万|#|2025-06-05|470.31万|-20.82%|117.92万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612103903a4a44987&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612103903a4a44987&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2542785793","title":"Inozyme Pharma, Inc.6月10日成交额为366.18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542785793","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542785793?lang=zh_cn&edition=full","pubTime":"2025-06-11 10:28","pubTimestamp":1749608910,"startTime":"0","endTime":"0","summary":"美东时间2025年6月10日,Inozyme Pharma, Inc.成交额为366.18万美元,成交额较昨日减少11.03%,当日成交量为92.05万股。Inozyme Pharma, Inc.于2025年6月10日涨0.0%,报3.98美元,该股过去5个交易日涨0.0%,年初至今涨43.68%,过去60日涨298.0%。该公司专注于开发一种新型疗法,以治疗 ENPP1 和 ABCC6 缺陷的罕见遗传病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611102841a702f13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611102841a702f13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2542435061","title":"Inozyme Pharma, Inc.6月9日成交额为411.56万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542435061","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542435061?lang=zh_cn&edition=full","pubTime":"2025-06-10 10:26","pubTimestamp":1749522398,"startTime":"0","endTime":"0","summary":"美东时间2025年6月9日,Inozyme Pharma, Inc.成交额为411.56万美元,成交额较昨日增加128.77%,当日成交量为103.42万股。Inozyme Pharma, Inc.于2025年6月9日跌0.25%,报3.98美元,该股过去5个交易日涨0.0%,年初至今涨43.68%,过去60日涨298.0%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-09|411.56万|128.77%|103.42万|#|2025-06-06|179.90万|-61.75%|45.10万|#|2025-06-05|470.31万|-20.82%|117.92万|#|2025-06-04|593.95万|45.64%|149.15万|#|2025-06-03|407.81万|-43.04%|102.38万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610102645a4a135e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610102645a4a135e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2541289059","title":"Inozyme Pharma, Inc.6月6日成交额为179.90万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541289059","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541289059?lang=zh_cn&edition=full","pubTime":"2025-06-07 10:25","pubTimestamp":1749263157,"startTime":"0","endTime":"0","summary":"美东时间2025年6月6日,Inozyme Pharma, Inc.成交额为179.90万美元,成交额较昨日减少61.75%,当日成交量为45.10万股。Inozyme Pharma, Inc.于2025年6月6日涨0.0%,报3.99美元,该股过去5个交易日涨0.5%,年初至今涨44.04%,过去60日涨269.44%。该公司专注于开发一种新型疗法,以治疗 ENPP1 和 ABCC6 缺陷的罕见遗传病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250607102603a49d8d70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250607102603a49d8d70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2541116170","title":"Inozyme Pharma, Inc.6月4日成交额为593.95万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541116170","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541116170?lang=zh_cn&edition=full","pubTime":"2025-06-05 10:25","pubTimestamp":1749090343,"startTime":"0","endTime":"0","summary":"美东时间2025年6月4日,Inozyme Pharma, Inc.成交额为593.95万美元,成交额较昨日增加45.64%,当日成交量为149.15万股。Inozyme Pharma, Inc.于2025年6月4日涨0.0%,报3.98美元,该股过去5个交易日涨0.51%,年初至今涨43.68%,过去60日涨275.47%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-04|593.95万|45.64%|149.15万|#|2025-06-03|407.81万|-43.04%|102.38万|#|2025-06-02|715.95万|65.69%|180.34万|#|2025-05-30|432.10万|-71.44%|109.12万|#|2025-05-29|1513.01万|-35.48%|382.51万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605102549a49aae01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605102549a49aae01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2540082892","title":"Inozyme Pharma, Inc.6月3日成交额为407.81万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540082892","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540082892?lang=zh_cn&edition=full","pubTime":"2025-06-04 10:25","pubTimestamp":1749003929,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日,Inozyme Pharma, Inc.成交额为407.81万美元,成交额较昨日减少43.04%,当日成交量为102.38万股。Inozyme Pharma, Inc.于2025年6月3日涨0.13%,报3.98美元,该股过去5个交易日涨0.51%,年初至今涨43.68%,过去60日涨246.09%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-03|407.81万|-43.04%|102.38万|#|2025-06-02|715.95万|65.69%|180.34万|#|2025-05-30|432.10万|-71.44%|109.12万|#|2025-05-29|1513.01万|-35.48%|382.51万|#|2025-05-28|2344.92万|417.71%|593.01万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604102536a6f97f85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604102536a6f97f85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2540489927","title":"Inozyme Pharma, Inc.6月2日成交额为715.95万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540489927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540489927?lang=zh_cn&edition=full","pubTime":"2025-06-03 10:24","pubTimestamp":1748917463,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日,Inozyme Pharma, Inc.成交额为715.95万美元,成交额较昨日增加65.69%,当日成交量为180.34万股。Inozyme Pharma, Inc.于2025年6月2日涨0.13%,报3.98美元,该股过去5个交易日涨0.38%,年初至今涨43.5%,过去60日涨223.17%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-06-02|715.95万|65.69%|180.34万|#|2025-05-30|432.10万|-71.44%|109.12万|#|2025-05-29|1513.01万|-35.48%|382.51万|#|2025-05-28|2344.92万|417.71%|593.01万|#|2025-05-27|452.94万|-1.28%|114.53万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603102428a6f7df68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603102428a6f7df68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2539152872","title":"Inozyme Pharma, Inc.5月29日成交额为1513.01万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539152872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539152872?lang=zh_cn&edition=full","pubTime":"2025-05-30 10:22","pubTimestamp":1748571759,"startTime":"0","endTime":"0","summary":"美东时间2025年5月29日,Inozyme Pharma, Inc.成交额为1513.01万美元,成交额较昨日减少35.48%,当日成交量为382.51万股。Inozyme Pharma, Inc.于2025年5月29日跌0.13%,报3.95美元,该股过去5个交易日涨0.0%,年初至今涨42.6%,过去60日涨252.68%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-29|1513.01万|-35.48%|382.51万|#|2025-05-28|2344.92万|417.71%|593.01万|#|2025-05-27|452.94万|-1.28%|114.53万|#|2025-05-23|458.83万|-41.71%|116.01万|#|2025-05-22|787.08万|-22.15%|199.04万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530102243a6f29c9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530102243a6f29c9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2538414257","title":"Inozyme Pharma, Inc.5月27日成交额为452.94万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538414257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538414257?lang=zh_cn&edition=full","pubTime":"2025-05-28 10:25","pubTimestamp":1748399109,"startTime":"0","endTime":"0","summary":"美东时间2025年5月27日,Inozyme Pharma, Inc.成交额为452.94万美元,成交额较昨日减少1.28%,当日成交量为114.53万股。Inozyme Pharma, Inc.于2025年5月27日跌0.13%,报3.96美元,该股过去5个交易日跌0.88%,年初至今涨42.78%,过去60日涨229.58%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-27|452.94万|-1.28%|114.53万|#|2025-05-23|458.83万|-41.71%|116.01万|#|2025-05-22|787.08万|-22.15%|199.04万|#|2025-05-21|1010.99万|-59.68%|255.67万|#|2025-05-20|2507.22万|-22.78%|633.93万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528102514a48f1a97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528102514a48f1a97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2538011171","title":"Inozyme制药公司和Biohaven制药公司宣布在行业重组期间进行领导层变动相关的帖子:Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring Related posts:","url":"https://stock-news.laohu8.com/highlight/detail?id=2538011171","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538011171?lang=zh_cn&edition=full","pubTime":"2025-05-26 17:05","pubTimestamp":1748250300,"startTime":"0","endTime":"0","summary":"by Mark Chiang马克·蒋Share To分享到The pharmaceutical industry has recently seen a series of notable personnel changes, including new hires, promotions, and departures across various companies. These movements reflect ongoing shifts within the sector as organizations adapt to evolving needs and strategies.制药行业近期出现了一系列显著的人事变动,包括多家公司的新聘、晋升和离职。Among the latest updates, Inozyme Pharma announced key leadership appointments aimed at advancing its therapeutic pipeline. Biohaven Pharmaceuticals reported internal promotions to bolster its executive team following recent expansions in its portfolio. PepGen disclosed the departure of a senior executive while simultaneously onboarding new talent to support its clinical development programs.在最新动态中,Inozyme Pharma宣布了关键的领导层任命,旨在推进其治疗产品线。Biohaven Pharmaceuticals在近期扩大产品组合后,报告了内部晋升以加强其执行团队。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505261709079502e72f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505261709079502e72f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2537312169","title":"Inozyme Pharma, Inc.5月23日成交额为458.83万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537312169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537312169?lang=zh_cn&edition=full","pubTime":"2025-05-24 10:11","pubTimestamp":1748052676,"startTime":"0","endTime":"0","summary":"美东时间2025年5月23日,Inozyme Pharma, Inc.成交额为458.83万美元,成交额较昨日减少41.71%,当日成交量为116.01万股。Inozyme Pharma, Inc.于2025年5月23日涨0.0%,报3.96美元,该股过去5个交易日涨0.25%,年初至今涨42.96%,过去60日涨230.0%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-23|458.83万|-41.71%|116.01万|#|2025-05-22|787.08万|-22.15%|199.04万|#|2025-05-21|1010.99万|-59.68%|255.67万|#|2025-05-20|2507.22万|-22.78%|633.93万|#|2025-05-19|3246.92万|-83.50%|820.40万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524101125a48a5623&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524101125a48a5623&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2537232309","title":"Inozyme Pharma, Inc.2025财年第一财季实现净利润-28.04百万美元,同比减少20.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537232309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537232309?lang=zh_cn&edition=full","pubTime":"2025-05-23 00:00","pubTimestamp":1747929629,"startTime":"0","endTime":"0","summary":"5月23日,Inozyme Pharma, Inc.公布财报,公告显示公司2025财年第一财季净利润为-28.04百万美元,同比减少20.09%;其中营业收入为0.00美元,每股基本收益为-0.44美元。机构评级:截至2025年5月23日,当前有7家机构对Inozyme Pharma, Inc.目标价做出预测,其中目标均价为6.86美元,其中最低目标价为4.00美元,最高目标价为16.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000055a6e91404&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000055a6e91404&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY"],"gpt_icon":0},{"id":"2537964880","title":"Inozyme Pharma, Inc.5月21日成交额为1010.99万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537964880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537964880?lang=zh_cn&edition=full","pubTime":"2025-05-22 10:12","pubTimestamp":1747879973,"startTime":"0","endTime":"0","summary":"美东时间2025年5月21日,Inozyme Pharma, Inc.成交额为1010.99万美元,成交额较昨日减少59.68%,当日成交量为255.67万股。Inozyme Pharma, Inc.于2025年5月21日涨0.0%,报3.95美元,该股过去5个交易日涨192.59%,年初至今涨42.6%,过去60日涨231.93%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-21|1010.99万|-59.68%|255.67万|#|2025-05-20|2507.22万|-22.78%|633.93万|#|2025-05-19|3246.92万|-83.50%|820.40万|#|2025-05-16|1.97亿|3601.03%|4987.88万|#|2025-05-15|531.77万|23.10%|363.26万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522101259a48787b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522101259a48787b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2537763586","title":"Inozyme Pharma, Inc.5月20日成交额为2507.22万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537763586","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537763586?lang=zh_cn&edition=full","pubTime":"2025-05-21 10:12","pubTimestamp":1747793525,"startTime":"0","endTime":"0","summary":"美东时间2025年5月20日,Inozyme Pharma, Inc.成交额为2507.22万美元,成交额较昨日减少22.78%,当日成交量为633.93万股。Inozyme Pharma, Inc.于2025年5月20日跌1.0%,报3.95美元,该股过去5个交易日涨262.39%,年初至今涨42.6%,过去60日涨218.55%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-20|2507.22万|-22.78%|633.93万|#|2025-05-19|3246.92万|-83.50%|820.40万|#|2025-05-16|1.97亿|3601.03%|4987.88万|#|2025-05-15|531.77万|23.10%|363.26万|#|2025-05-14|431.99万|310.07%|356.16万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521101207a6e6b9ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521101207a6e6b9ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2536668941","title":"Inozyme Pharma, Inc.5月19日成交额为3246.92万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536668941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536668941?lang=zh_cn&edition=full","pubTime":"2025-05-20 10:05","pubTimestamp":1747706757,"startTime":"0","endTime":"0","summary":"美东时间2025年5月19日,Inozyme Pharma, Inc.成交额为3246.92万美元,成交额较昨日减少83.50%,当日成交量为820.40万股。Inozyme Pharma, Inc.于2025年5月19日涨1.01%,报3.99美元,该股过去5个交易日涨238.14%,年初至今涨44.04%,过去60日涨219.2%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-05-19|3246.92万|-83.50%|820.40万|#|2025-05-16|1.97亿|3601.03%|4987.88万|#|2025-05-15|531.77万|23.10%|363.26万|#|2025-05-14|431.99万|310.07%|356.16万|#|2025-05-13|105.34万|41.56%|97.61万|Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520100606a6e5671a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520100606a6e5671a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2536345438","title":"Needham:下调Inozyme Pharma评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2536345438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536345438?lang=zh_cn&edition=full","pubTime":"2025-05-17 01:12","pubTimestamp":1747415550,"startTime":"0","endTime":"0","summary":"Needham:下调Inozyme Pharma(INZY.US)评级,由买入调整至持有评级,目标价由12.00美元调整至12.00美元。Inozyme Pharma(INZY.US)公司简介:Inozyme Pharma是一家临床阶段的罕见病生物制药公司,致力于开发用于治疗影响血管、软组织和骨骼疾病的新型治疗方法。该公司致力于开发治疗方法,以解决这些令人痛苦的疾病的根本原因。该公司专注于开发一种新型疗法,用于治疗ENPP1和ABCC6缺陷这两种罕见遗传病。该公司的产品候选药物INZ-701是一种可溶性、重组、基因工程融合蛋白,旨在纠正涉及ENPP1和ABCC6缺陷的通路缺陷。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517011511a48129ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517011511a48129ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY"],"gpt_icon":0},{"id":"2535315750","title":"Inozyme Pharma, Inc.盘中异动 早盘快速拉升177.46%报3.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535315750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535315750?lang=zh_cn&edition=full","pubTime":"2025-05-16 21:31","pubTimestamp":1747402285,"startTime":"0","endTime":"0","summary":"北京时间2025年05月16日21时31分,Inozyme Pharma, Inc.股票出现波动,股价急速上涨177.46%。Inozyme Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.15%。Inozyme Pharma, Inc.公司简介:Inozyme Pharma Inc 是一家临床阶段的生物制药公司,开发用于治疗影响骨骼健康和血管功能的疾病的新型疗法。该信息摘要如下:Needham:维持Inozyme Pharma评级,由买入调整至买入评级, 目标价由15.00美元调整至12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516213126a480f787&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516213126a480f787&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2535009459","title":"Needham:维持Inozyme Pharma评级,由买入调整至买入评级, 目标价由15.00美元调整至12.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535009459","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535009459?lang=zh_cn&edition=full","pubTime":"2025-05-15 02:33","pubTimestamp":1747247617,"startTime":"0","endTime":"0","summary":"Needham:维持Inozyme Pharma(INZY.US)评级,由买入调整至买入评级, 目标价由15.00美元调整至12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505150237269759bc96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505150237269759bc96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INZY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inozyme.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.005},{"period":"3month","weight":3.5142},{"period":"6month","weight":1.005},{"period":"1year","weight":-0.1342},{"period":"ytd","weight":0.444}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":0.0377},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0781},{"period":"1year","weight":0.1149},{"period":"ytd","weight":0.0678}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inozyme Pharma, Inc.根据特拉华州法律成立于2015年9月。该公司是一家罕见的疾病生物制药公司,致力于开发新颖的疗法来治疗影响血管,软组织和骨骼的异常矿化疾病。通过对矿化所涉及的生物途径的深入了解,该公司致力于开发治疗剂以解决这些使人衰弱的疾病的根本原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.22291},{"month":2,"riseRate":0.4,"avgChangeRate":-0.005308},{"month":3,"riseRate":0.4,"avgChangeRate":0.137262},{"month":4,"riseRate":0.2,"avgChangeRate":-0.059967},{"month":5,"riseRate":0.6,"avgChangeRate":0.490343},{"month":6,"riseRate":0.6,"avgChangeRate":0.0394},{"month":7,"riseRate":0.2,"avgChangeRate":-0.005239},{"month":8,"riseRate":0.2,"avgChangeRate":0.036393},{"month":9,"riseRate":0,"avgChangeRate":-0.135388},{"month":10,"riseRate":0,"avgChangeRate":-0.227258},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05305},{"month":12,"riseRate":0.4,"avgChangeRate":-0.09901}],"exchange":"NASDAQ","name":"Inozyme Pharma","nameEN":"Inozyme Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inozyme Pharma(INZY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inozyme Pharma(INZY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inozyme Pharma,INZY,Inozyme Pharma股票,Inozyme Pharma股票老虎,Inozyme Pharma股票老虎国际,Inozyme Pharma行情,Inozyme Pharma股票行情,Inozyme Pharma股价,Inozyme Pharma股市,Inozyme Pharma股票价格,Inozyme Pharma股票交易,Inozyme Pharma股票购买,Inozyme Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inozyme Pharma(INZY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inozyme Pharma(INZY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}